Department of Global Health, School of Public Health, Boston University, Boston, MA, USA.
Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
J Int AIDS Soc. 2021 Apr;24(4):e25692. doi: 10.1002/jia2.25692.
Lesotho, the country with the second-highest HIV/AIDS prevalence (23.6%) in the world, has made considerable progress towards achieving the "95-95-95" UNAIDS targets, but recent success in improving treatment access to all known HIV positive individuals has severely strained existing healthcare infrastructure, financial and human resources. Lesotho also faces the challenge of a largely rural population who incur a significant time and financial burden to visit healthcare facilities. Using data from a cluster-randomized non-inferiority trial conducted between August 2017 and July 2019, we evaluated costs to providers and costs to patients of community-based differentiated models of multi-month delivery of antiretroviral therapy (ART) in Lesotho.
The trial of multi-month dispensing compared 12-month retention in care among three arms: conventional care, which required quarterly facility visits and ART dispensation (3MF); three-month community adherence groups (CAGs) (3MC) and six-month community ART distribution (6MCD). We first estimated the average total annual cost of providing HIV care and treatment followed by the total cost per patient retained 12 months after entry for each arm, using resource utilization data from the trial and local unit costs. We then estimated the average annual cost to patients in each arm with self-reported questionnaire data.
The average total annual cost of providing HIV care and treatment per patient was the highest in the 3MF arm ($122.28, standard deviation [SD] $23.91), followed by 3MC ($114.20, SD $23.03) and the 6MCD arm ($112.58, SD $21.44). Per patient retained in care, the average provider cost was $125.99 (SD $24.64) in the 3MF arm and 6% to 8% less for the other two arms ($118.38, SD $23.87 and $118.83, SD $22.63 for the 3MC and 6MCD respectively). There was a large reduction in patient costs for both differentiated service delivery arms: from $44.42 (SD $12.06) annually in the 3MF arm to $16.34 (SD $5.11) annually in the 3MC (63% reduction) and $18.77 (SD $8.31) annually in 6MCD arm (58% reduction).
Community-based, multi-month models of ART in Lesotho are likely to produce small cost savings to treatment providers and large savings to patients in Lesotho. Patient cost savings may support long-term adherence and retention in care.
莱索托是世界上艾滋病毒/艾滋病感染率第二高(23.6%)的国家,在实现联合国艾滋病规划署的“95-95-95”目标方面取得了相当大的进展,但最近在为所有已知艾滋病毒阳性者改善治疗获取方面取得的成功,严重影响了现有的医疗保健基础设施、财政和人力资源。莱索托还面临着一个主要是农村人口的挑战,他们在前往医疗设施方面会产生相当大的时间和经济负担。本研究利用 2017 年 8 月至 2019 年 7 月期间进行的一项非劣效性集群随机试验的数据,评估了莱索托基于社区的、多模式提供抗逆转录病毒疗法(ART)对提供者和患者的成本。
多模式配送试验比较了三个方案 12 个月的护理保留率:常规护理,每季度需要到医疗机构就诊并领取 ART(3MF);三个月社区依从性小组(3MC)和六个月社区 ART 发放(6MCD)。我们首先使用试验中的资源利用数据和当地单位成本,估计每个方案中提供 HIV 护理和治疗的平均年度总成本,然后再估计每个方案中每个接受治疗 12 个月的患者的总成本。我们随后使用自我报告问卷数据估计每个方案中患者的平均年度成本。
提供 HIV 护理和治疗的患者平均年度总成本最高的是 3MF 方案($122.28,标准差[SD] $23.91),其次是 3MC 方案($114.20,SD $23.03)和 6MCD 方案($112.58,SD $21.44)。在保留护理的患者中,3MF 方案的平均提供者成本为$125.99(SD $24.64),而其他两个方案的成本要低 6%至 8%($118.38,SD $23.87 和$118.83,SD $22.63 分别为 3MC 和 6MCD 方案)。对于两种差异化服务提供方案,患者的成本都有大幅降低:从 3MF 方案的$44.42(SD $12.06)/年降低到 3MC 方案的$16.34(SD $5.11)/年(降低 63%)和 6MCD 方案的$18.77(SD $8.31)/年(降低 58%)。
莱索托基于社区的、多模式的 ART 模式可能会为治疗提供者带来少量的成本节约,同时为莱索托的患者带来较大的成本节约。患者成本节约可能会支持长期的依从性和护理保留。